Vivos Therapeutics (VVOS) Accumulated Depreciation & Amortization (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accumulated Depreciation & Amortization data on file, last reported at $3.2 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization rose 31.14% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 31.14% YoY) and the FY2025 annual result came in at $2.9 million, up 5.61% from the prior year.
• Accumulated Depreciation & Amortization advanced to $3.2 million in Q1 2026 per VVOS's latest filing, from $2.9 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $3.2 million in Q1 2026 and bottomed at $1.3 million in Q1 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $2.4 million (2025), against an average of $2.3 million.
• The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization surged 50.35%; it then slipped 1.26% in 2025.
• Tracing VVOS's Accumulated Depreciation & Amortization over 5 years: stood at $1.8 million in 2022, then surged by 32.69% to $2.3 million in 2023, then grew by 19.52% to $2.8 million in 2024, then advanced by 5.61% to $2.9 million in 2025, then grew by 8.45% to $3.2 million in 2026.
• Per Business Quant, the three latest VVOS Accumulated Depreciation & Amortization figures stand at $3.2 million (Q1 2026), $2.9 million (Q4 2025), and $3.0 million (Q3 2025).

Peer Comparison